课题基金 / 基金详情

CORE--CLINICAL RESEARCH RESOURCES

CORE--CLINICAL RESEARCH RESOURCES
核心--临床研究资源
批准号:
6315254
负责人:
RUTH ORATZ
金额:
$13.42万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-05-19 至 2002-11-30

项目摘要

项目成果

RUTH ORATZ的其他基金

相关文献

中文摘要
翻译
临床研究资源(CRR)单位协调行政管理 以及为会员进行的临床研究提供病人护理服务 卡普兰综合癌症中心。中央档案室参与了 从方案构思到临床试验的实施 从实施到完成的多个层次的审查。CRR 现在包括临床试验办公室和患者的服务 研究资源,整合与协议相关的所有服务 在一个单位进行管理。因此,合并后的单位名称为 现在是临床研究资源。 在数据收集、记录和分析方面进行了许多改进 自1993年核心赠款提交以来采用。CRR还进一步 加强所有与癌症有关的议定书审查工作的协调 由该中心的各种临床共享资源,临床 执行管理委员会、其他内部审查委员会和 外部机构。它还提高了文化水平和文化水平 护理人员的多样性。拥有新的临床设施, 地点和规划,CRR的职能已成为必不可少的 患者护理和临床研究的最佳结合 纽约大学医学中心大型多样的临床环境。
英文摘要
The Clinical Research Resources (CRR) unit coordinates administrative and patient care services for the clinical research conducted by members of the Kaplan Comprehensive Cancer Center. The CRR is involved in the performance of a clinical trial from conception of the protocol through the multiple levels of review to implementation and completion. The CRR now includes the services of the Clinical Trials Office and Patient Research Resource, to incorporate all services concerning protocol management in one unit. Accordingly, the name of the combined unit is now Clinical Research Resources. Many enhancements in data collection, recording and analysis have been introduced since the 1993 Core grant presentation. The CRR has further improve the coordination of the review of all cancer related protocols by the Center's various clinical shared resources, the Clinical Executive Management Committee, other internal review committees and external agencies. It also has increased the level and cultural diversity of its nursing personnel. With new clinical facilities both in place and planned, the functions of the CRR have become essential for the optimal coupling of patient care and clinical research within the large and diverse clinical setting of NYU Medical Center.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BRYOSTATIN 1 (NSC339555) & CISPLATIN IN ADVANCED MALIGNANCIES
CORE--CLINICAL RESEARCH RESOURCES
INTERLEUKIN 2 + HISTAMINE VERSUS INTERLEUKIN 2 IN ADVANCE MALIGNANT MELANOMA
BRYOSTATIN 1 (NSC339555) & CISPLATIN IN ADVANCED MALIGNANCIES